Newly approved medications for various types of pain, generalized myasthenia gravis, and Parkinson disease will be fodder for discussion at AAN 2018. Here’s a brief overview of the therapies the FDA has approved within the past 6 months.
Newly approved treatments for several neurologic disorders-including various types of pain, generalized myasthenia gravis, and Parkinson Disease-will be topics of discussion at AAN 2018. Here’s a brief overview of those medications FDA approved within the past 6 months.
Here's a brief overview of 6 newly approved medications indicated for management of various types of pain (post-herpetic, acute, neuropathic); for Parkinson disease and drug-induced extrapyramidal reactions; for herpes zoster prophylaxis; and for selected patients with generalized myasthenia gravis.
Postherpetic Neuralgia:ZTlido (lidocaine topical system) 1.8%, a transdermal anesthetic patch for the treatment of post-shingles pain. The ZTlido patch delivers 1.8% of lidocaine for up to 12-hours of relief. (Approved 02/28/18, Scilex Pharmaceuticals, Inc.) ©Tatiana Shepeleva/Shutterstock.com
Acute Pain:Apadaz (acetaminophen and benzhydrocodone hydrochloride) Tablets, an immediate release combination of acetaminophen and benzhydrocodone approved for the short-term (no more than 14 days) management of acute pain. (Approved 02/23/18, KemPharm, Inc.) ©Sjstudio6/Shutterstock.com
Parkinson's Disease, Extrapyramidal Reaction: Osmolex ER (amantadine hydrochloride) is a proprietary formulation of immediate release and extended release amantadine for the once-a-day treatment of Parkinson’s disease and drug-induced extrapyramidal reactions. Three dosage options are available: 129 mg, 193 mg and 258 mg tablets; with a maximum daily dose is 322 mg. (Approved 02/19/18, Osmotica Pharmaceutical US LLC)
Neuropathic pain: Lyrica CR (Pregabalin) extended release tablets are approved as once-daily therapy for management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. Lyrica CR did not receive approval for the management of fibromyalgia. (Approved 10/12/17, Pfizer Inc.) ©Michael Taylor/Shutterstock.com
Herpes Zoster Prophylaxis: Shingrix (zoster vaccine recombinant, adjuvanted) Injection is a non-live, recombinant subunit vaccine for the prevention of herpes zoster in adults aged 50 years and older. Given IM in two doses. (Approved 10/20/17, GlaxoSmithKline) ©Topkati/Shutterstock.com
Generalized Myasthenia Gravis (for patients who are anti-acetylcholine receptor antibody-positive: Soliris (eculizumab) is a first-in-class complement inhibitor that works by inhibiting the terminal part of the complement cascade that, when activated in an uncontrolled manner, plays a role in serious ultra-rare disorders like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and anti-acetylcholine receptor (AchR) antibody-positive myasthenia gravis (MG). "This is a landmark day for the members of the US myasthenia gravis community, who have not seen a therapy approved for generalized myasthenia gravis in more than 60 years,” said Nancy Law, Chief Executive Officer of the Myasthenia Gravis Foundation of America.” (Approved 10/23/17, Alexion Pharmaceuticals) ©Alila Medical Media/Shutterstock.com